New guidelines for data protection in Mexico are “good news” for innovators and brands, say Hedwig Lindner and Manuel Morante.
Clinical data is protected in Mexico under Article 1711 of the North American Free Trade Agreement (NAFTA) (in force since January 1, 1994), and Article 39.3 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) (in force since January 1, 1995). However, there is no consensus as to whether NAFTA embraces the concept of data exclusivity.
After NAFTA entered into force, the Mexican Congress amended the Industrial Property Law by adding Article 86 bis, which states: “The information required by special laws to determine the safety and efficacy of pharmaceutical and agricultural products that make use of new chemical components shall be protected under the terms of the international agreements to which Mexico is a ratifying party.”
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
data protection, TRIPS, COFEPRIS, pharmaceuticals